目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T78702 | Phosphatase | ||
PTP1B/AKR1B1-IN-1是一种针对PTP1B和AKR1B1的双重抑制剂,其IC50值分别为0.06 μM和4.3 μM。该化合物也能抑制TC-PTP,IC50为9 μM。在小鼠成肌细胞中,PTP1B/AKR1B1-IN-1作为胰岛素模拟剂使用,并能减少AKR1B1依赖的山梨醇积累,有助于抑制2型糖尿病的发展并控制血糖水平。 | |||
T60401 | |||
Tezacitabine 是一种抑制细胞生长和细胞毒性的抗代谢物。 Tezacitabine 是一种核苷类似物,具有双重作用机制。 Tezacitabine 不可逆地抑制核糖核苷酸还原酶,并可在复制或修复过程中掺入 DNA,导致 DNA 链终止。 Tezacitabine 在细胞周期的 G1 期和 S 期阻断肿瘤细胞并诱导凋亡细胞死亡。 Tezacitabine 具有治疗白血病和实体瘤的潜力[1][2]。 | |||
T68219 | |||
Peraclopone is a hypolidemic drug. It is an inhibitor of 7-Dehydrocholesterol reductase. Peraclopone potently inhibits the final step in cholesterol biosynthesis. Feeding this agent to rats leads to a rapid replacement of membrane cholesterol with its immediate precursor 7-dehydrocholesterol, and a dramatic reduction in plasma sterol concentration. Peraclopone caused a dose-dependent decrease in cholesterol and a concomitant accumulation of provitamin D3 (7-dehydrocholesterol) in the skin, which is accompanied by an increase in the plasma level of 25-hydroxyvitamin D3. Treatment with peraclopone dramatically alters membrane sterol content in many membranes including the microvillus membrane of both the jejunum and ileum. In the jejunal microvillus membrane a major change in chemical composition occurred, presumably in response to the alteration in membrane sterol. The net result was a significant decline in both the static and dynamic component of membrane fluidity. | |||
T82900 | |||
Bemfivastatin (PPD 10558) hemicalcium 作为口服HMG-CoA还原酶抑制剂,具备有效的降脂作用并能增强肝脏提取活性。该化合物的未观察到不良反应水平(NOAEL)在大鼠发育毒性研究中超过320 mg/kg/d,在家兔母体毒性及发育毒性研究中分别超过12.5 mg/kg/d和25 mg/kg/d。Bemfivastatin hemicalcium 适用于对他汀类药物不耐受且患有他汀相关性高胆固醇血症性肌痛的研究。 | |||
T36564 | |||
Acenocoumarol is a short-lived oral anti-coagulant, which, like warfarin, functions by inhibiting vitamin K epoxide reductase. It has higher intrinsic anticoagulant potency than warfarin and phenprocoumon, when evaluated in vitro. Acenocoumarol has a single chiral center that gives rise to two different enantiomeric forms. (S)-Acenocoumarol has a shorter plasma elimination half-life (1.8 hours) and faster plasma clearance (28.5 L/hour), compared to the (R)-enantiomer (6.6 hours, 1.9 L/hour). The S-enantiomer undergoes extensive first-pass metabolism during absorption from the gastrointestinal tract, whereas (R)-acenocoumarol is rapidly absorbed and provides essentially complete oral bioavailability. Perhaps related to these pharmacokinetic characteristics, (S)-acenocoumarol is less potent in vivo as an anti-coagulant than the (R)-enantiomer. As the clearance of acenocoumarol is ~20-fold faster than that for warfarin, the plasma concentrations of acenocoumarol are substantially lower than those for warfarin in patients receiving long-term treatment. | |||
TN5153 | MMP ERK IκB/IKK p38 MAPK NF-κB Tyrosinase Reductase DNA/RNA Synthesis JNK | ||
Torilin 是一种睾酮5α还原酶抑制剂,它(IC50=31.7+/-4.23μM)对5α还原酶的抑制作用强于α-亚麻酸(IC50=160.3+/-24.62μM),但弱于非那雄胺(IC50=0.38+/-0.06μM)。Torilin 具有免疫调节、肝脏保护和抗炎特性,它通过限制 TAK1介导的 MAP 激酶和 NF-βB 活化来抑制炎症,它可以减轻关节炎的严重程度,改变 dLN 或关节中的白细胞活化,并恢复血清和脾细胞细胞因子失衡。托利林抑制α-黑素细胞刺激激素激活的 B16黑色素瘤细胞中的黑色素生成,IC(50)值为25μM。Torilin 对枯草芽孢杆菌 ATCC 6633孢子和营养细胞表现出优异的抗菌活性。Torilin 在体内和体外都具有强大的抗血管生成活性,它可能通过抑制肿瘤侵袭来抑制肿瘤发生,逆转癌细胞的多药耐药性,它可以增强阿霉素、长春碱、紫杉醇和秋水仙碱对多药耐药 KB-V1和 MCF7/ADR 细胞的细胞毒性。 | |||
T79735 | |||
DHFR-IN-9(化合物8A)是一种二氢叶酸还原酶(DHFR)抑制剂,通过干扰细胞内嘌呤和胸苷酸的生物合成而影响细胞生长和增殖。该化合物对抗耐甲氧西林金黄色葡萄球菌(MRSA)ATCC 43300展现出显著的抑制效果(IC50=0.25 μg/mL),并在全身及大腿感染的小鼠模型中显示出抗感染能力(剂量:2.5 mg/kg,5 mg/kg;ip)。此外,DHFR-IN-9在乳腺癌小鼠模型中展示了超过紫杉醇(Y-B0015)的抗癌活性(剂量:2.5 mg/kg;ip;每3天1次)。 | |||
T36137 | |||
Biotin (S)-sulfoxide is an inactive metabolite of the coenzyme biotin .1,2It has also been found inE. coliand is reduced by the biotin sulfoxide reduction system as a source of biotin.3 1.Denkel, L.A., Rhen, M., and Bange, F.-C.Biotin sulfoxide reductase contributes to oxidative stress tolerance and virulence in Salmonella enterica serovar TyphimuriumMicrobiology (Reading)159(Pt 7)1447-1458(2013) 2.Carling, R.S., and Turner, C.Methods for assessment of biotin (Vitamin B7)Laboratory assessment of vitamin status193-217(2019) 3.del Campillo-Campbell, A., Dykhuizen, D., and Clearly, P.P.Enzymic reduction of d-biotin d-sulfoxide to d-biotinMethods Enzymol.62379-385(1979) | |||
T22672 | Others | ||
steroidal androgen receptor agonist |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-00288 | Adrenodoxin reductase Protein, Bovine, Recombinant (His) | Bovine | Yeast | ||
Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver.
|
|||||
TMPH-01224 | Dihydrofolate reductase Protein, Human, Recombinant (His) | Human | E. coli | ||
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2.
|
|||||
TMPH-00287 | Adrenodoxin reductase Protein, Bovine, Recombinant (E. coli, His) | Bovine | E. coli | ||
Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver.
|
|||||
TMPH-00608 | Dihydrofolate reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
|
|||||
TMPH-03535 | Dihydrofolate reductase Protein, S. aureus, Recombinant (His & Myc) | Staphylococcus aureus | E. coli | ||
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
|
|||||
TMPH-03581 | Dihydrofolate reductase Protein, S. epidermidis, Recombinant (His) | Staphylococcus epidermidis | E. coli | ||
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
|
|||||
TMPH-00218 | DHCR7 Protein, Bovine, Recombinant (His) | Bovine | in vitro E. coli expression system | ||
7-dehydrocholesterol reductase of the cholesterol biosynthetic pathway reducing the C7-C8 double bond of cholesta-5,7-dien-3beta-ol (7-dehydrocholesterol/7-DHC) and cholesta-5,7,24-trien-3beta-ol, two intermediates in that pathway.
|
|||||
TMPJ-00937 | RRM2 Protein, Human, Recombinant (His) | Human | Human Cells | ||
Ribonucleoside-Diphosphate Reductase Subunit M2 (RRM2) belongs to the ribonucleoside diphosphate reductase small chain family. The reductase of RRM2 catalyzes the formation of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. RRM2 supplies the precursors essential for DNA synthesis. RRM2 catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Phosphorylation on Ser-20 relieves the inhibitory effect on Wnt signaling.
|
|||||
TMPJ-00813 | QDPR Protein, Human, Recombinant (His) | Human | Human Cells | ||
Dihydropteridine reductase, also known as HDHPR and Quinoid dihydropteridine reductase, QDPR and DHPR, belongs to the short-chain dehydrogenases/reductases (SDR) family. QDPR exists as a homodimer. QDPR is part of the pathway that recycles a substance called tetrahydrobiopterin, also known as BH4 and tryptophan hydroxylases. The regeneration of this substance is critical for the proper processing of several other amino acids in the body. Tetrahydrobiopterin also helps produce certain chemicals in the brain called neurotransmitters, which transmit signals between nerve cells. Defects in QDPR are the cause of BH4-deficient hyperphenylalaninemia type C (HPABH4C) which is a rare autosomal recessive disorder and is lethal.
|
|||||
TMPJ-01009 | BLVRA Protein, Human, Recombinant (His) | Human | E. coli | ||
Human Biliverdin reductase A (BLVRA) is belonged to the Gfo/Idh/MocA family and Biliverdin reductase subfamily. BLVRA is an enzyme that in humans is encoded by the BLVRA gene. BLVRA plays an important role in reducing the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor. BLVRA acts on biliverdin by reducing its double-bond between the pyrrole rings into a single-bond. It accomplishes this using NADPH + H+ as an electron donor, forming bilirubin and NADP+ as products.
|
|||||
TMPH-03008 | ENR Protein, Mycobacterium tuberculosis, Recombinant (His) | Mycobacterium tuberculosis | E. coli | ||
Enoyl-ACP reductase of the type II fatty acid syntase (FAS-II) system, which is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls. Catalyzes the NADH-dependent reduction of the double bond of 2-trans-enoyl-[acyl-carrier protein], an essential step in the fatty acid elongation cycle of the FAS-II pathway. Shows preference for long-chain fatty acyl thioester substrates (>C16), and can also use 2-trans-enoyl-CoAs as alternative substrates. The mycobacterial FAS-II system utilizes the products of the FAS-I system as primers to extend fatty acyl chain lengths up to C56, forming the meromycolate chain that serves as the precursor for final mycolic acids.; Is the primary target of the first-line antitubercular drug isoniazid (INH) and of the second-line drug ethionamide (ETH). Overexpressed inhA confers INH and ETH resistance to M.tuberculosis. The mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of NAD and binding of the INH-NAD adduct to the active site of InhA. Similarly, the ETH-NAD adduct binds InhA.
|
|||||
TMPY-03617 | GMPR Protein, Human, Recombinant (His) | Human | E. coli | ||
GMPR, also known as GMPR1, belongs to the IMPDH/GMPR family.This familyofenzymesincludesIMP dehydrogenaseandGMP reductase. These enzymes are involved inpurine metabolism and adopt aTIM barrelstructure. GMPR is an enzyme that catalyzes the irreversible and NADPH-dependent reductive deamination of GMP to IMP. GMPR functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides.
|
|||||
TMPY-00538 | MSRB3 Protein, Human, Recombinant (His) | Human | HEK293 | ||
MSRB3 (Methionine Sulfoxide Reductase B3) is a Protein Coding gene. The protein encoded by this gene catalyzes the reduction of methionine sulfoxide to methionine. This enzyme acts as a monomer and requires zinc as a cofactor. This cysteine residue of MSRB3 is conserved in orthologs from yeast to humans and is involved in binding structural zinc. The affected individuals of six unrelated families were homozygous for the same transversion (c.265T>G) in MSRB3. In the inner ear, it is found in the sensory epithelium of the organ of Corti and vestibular end organs as well as in cells of the spiral ganglion. MSRB3-catalyzed reduction of methionine sulfoxides to methionine is essential for hearing. Diseases associated with MSRB3 include Deafness, Autosomal Recessive 74, and Autosomal Recessive Non-Syndromic Sensorineural Deafness Type Dfnb.
|
|||||
TMPY-00354 | MSRB3 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
MSRB3 (Methionine Sulfoxide Reductase B3) is a Protein Coding gene. The protein encoded by this gene catalyzes the reduction of methionine sulfoxide to methionine. This enzyme acts as a monomer and requires zinc as a cofactor. This cysteine residue of MSRB3 is conserved in orthologs from yeast to humans and is involved in binding structural zinc. The affected individuals of six unrelated families were homozygous for the same transversion (c.265T>G) in MSRB3. In the inner ear, it is found in the sensory epithelium of the organ of Corti and vestibular end organs as well as in cells of the spiral ganglion. MSRB3-catalyzed reduction of methionine sulfoxides to methionine is essential for hearing. Diseases associated with MSRB3 include Deafness, Autosomal Recessive 74, and Autosomal Recessive Non-Syndromic Sensorineural Deafness Type Dfnb.
|
|||||
TMPY-03867 | CBR3 Protein, Human, Recombinant (His) | Human | E. coli | ||
CBR3, also known as hCBR3, belongs to the short-chain dehydrogenases/reductases (SDR) family. CBR3 is expressed in ovary, pancreas, intestine, colon, kidney, brain, thymus, lung, heart, liver, spleen, leukocyte, prostate and testis. It is a monomeric NADPH-dependent oxidoreductase and is closely linked to another carbonyl reductase gene – CBR1. CBR3 catalyzes the reduction of a large number of biologically and pharmacologically active carbonyl compounds to their corresponding alcohols. It has low NADPH-dependent oxidoreductase activity towards 4-benzoylpyridine and menadione (in vitro).
|
|||||
TMPY-02438 | AKR1B1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Aldose reductase (AKR1B1) belongs to the aldo/keto reductase superfamily. AKR1B1 is a NADPH-dependent aldo-keto reductase best known as the rate-limiting enzyme of the polyol pathway. Expression of AKR1B1 was the highest in lens and retina. It is the first enzyme in the polyol pathway through which glucose is converted to sorbitol which is important for the function of various organs in the body, and has been implicated in the etiology of diabetic complications. AKR1B1 is quite abundant in the collecting tubule cells and thought to provide protection against hypertonic environment. Some human tissues contain AKR1B1 as well as AKR1B10, a closely related member of the aldo-keto reductase superfamily.
|
|||||
TMPY-02461 | AKR1A1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Aldehyde reductase (AKR1A1) is a member of the aldo-keto reductase superfamily, which consists of more than 40 known enzymes and proteins that includes variety of monomeric NADPH-dependent oxidoreductases, such as aldehyde reductase. Aldehyde reductase has wide substrate specificities for carbonyl compounds. These enzymes are implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Aldehyde reductase possess a structure with a beta-alpha-beta fold which contains a novel NADP-binding motif. The binding site is located in a large, deep, elliptical pocket in the C-terminal end of the beta sheet, the substrate being bound in an extended conformation. This binding is more similar to FAD- than to NAD(P)-binding oxidoreductases. AKR1A1 is involved in the reduction of biogenic and xenobiotic aldehydes and is present in virtually every tissue.
|
|||||
TMPY-03287 | RRM1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
RRM1 is a subunit of ribonucleoside-diphosphate reductase which is constituted by two subunits. Ribonucleoside-diphosphate reductase is an enzyme essential for the production of deoxyribonucleotides prior to DNA synthesis in S phase of dividing cells. RRM1 is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. RRM1 may play a role in malignancies and disease that involve this region.
|
|||||
TMPY-02527 | p53R2 Protein, Human, Recombinant (His) | Human | E. coli | ||
Ribonucleoside reductase subunit M2B, also known as RRM2B or p53R2, is an enzyme belonging to the iron-dependent ribonucleotide reductase (RNR) enzyme family which is essential for DNA synthesis. Ribonucleotide reductase (RNR) is an enzyme that catalyzes the formation of deoxyribonucleotides from ribonucleotides and plays a critical role in regulating the total rate of DNA synthesis so that DNA to cell mass is maintained at a constant ratio during cell division and DNA repair. RRM2B is a phosphorylated protein. It is hypothesized that RRM2B activity can be regulated at the posttranslational level in response to DNA damage. RRM2B has previously been shown to be essential for the maintenance of mtDNA copy number and its candidacy for tumor suppression has been evaluated in several mutational analyses of different cancer types. However, the contribution of RRM2B to the DNA damage response has been questioned because its transcriptional induction upon DNA damage is not rapid enough for prompt DNA repair. Instead, ATM-mediated phosphorylation has been suggested to regulate the DNA repair activity of RRM2B posttranslationally. Besides, a defect in RRM2B can induce a mild muscle disease of adult onset through disturbance of mitochondrial homeostasis but that this defect does not appear to be oncogenic.
|
|||||
TMPH-02498 | AKR1C3 Protein, Mouse, Recombinant (His & Myc) | Mouse | E. coli | ||
Catalyzes the dehydrogenation of 17-beta-hydroxysteroids. May also exhibit significant activity with a variety of cyclic and alicyclic alcohols. Uses both NAD and NADP, but the activity is much greater with NAD than with NADP.
|
|||||
TMPY-02519 | BLVRB Protein, Human, Recombinant (His) | Human | E. coli | ||
Biliverdin reductase (hBVR) is a serine/threonine kinase that catalyzes reduction of the heme oxygenase (HO) activity product, biliverdin, to bilirubin. BVR consists of an N-terminal dinucleotide-binding domain (Rossmann-fold) and a C-terminal domain that contains a six-stranded β-sheet that is flanked on one face by several α-helices. The C-terminal and N-terminal domains interact extensively, forming the active site cleft at their interface. Biliverdin reductase (BVR) catalyzes the last step in heme degradation by reducing the γ-methene bridge of the open tetrapyrrole, biliverdin IXα, to bilirubin with the concomitant oxidation of a β-nicotinamide adenine dinucleotide (NADH) or β-nicotinamide adenine dinucleotide phosphate (NADPH) cofactor. It is now recognized that human BVR (hBVR) is a dual-specificity kinase (Ser / Thr and Tyr) upstream activator of the insulin/insulin growth factor-1 (IGF-1) and mitogen-activated protein kinase (MAPK) signaling pathways. Human BVR (hBVR) is essential for MAPK-extracellular signal-regulated kinase (ERK)1/2 (MEK)-eukaryotic-like protein kinase (Elk) signaling and has been identified as the cytoplasm-nuclear heme transporter of ERK1/2 and hematin, the key components of stress-responsive gene expression.
|
|||||
TMPH-02801 | CYPOR Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
CYPOR Protein, Mouse, Recombinant (His) is expressed in E. coli.
|
|||||
TMPH-01748 | CYPOR Protein, Human, Recombinant (GST) | Human | E. coli | ||
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
|
|||||
TMPH-00625 | FMN reductase Protein, E. coli, Recombinant (His) | E. coli | Baculovirus | ||
Catalyzes an NADPH-dependent reduction of FMN, but is also able to reduce FAD or riboflavin.
|
|||||
TMPH-00097 | AtAER Protein, Arabidopsis thaliana, Recombinant (His & SUMO) | Arabidopsis thaliana | E. coli | ||
Involved in the detoxification of reactive carbonyls. Acts on lipid peroxide-derived reactive aldehydes. Specific to a double bond activated by an adjacent carbonyl group. Can use both quinones and diamide as substrates, but not menadione, ferricyanide or phylloquinone. Can use 4-hydroxy-(2E)-nonenal (HNE), 4-hydroxy-(2E)-hexenal (HHE), (2E)-nonenal, (2E)-hexenal, (2E)-pentenal, propenal (acrolein), 3-buten-2-one and 3-penten-2-one, but not (R)-(-)-carvone, n-nonanal, n-hexanal, (3Z)-hexanal, cyclohex-2-en-1-one or 12-oxo phytodienoic acid (OPDA) as electron acceptors. Catalyzes the reduction of the alpha,beta-unsaturated bond of 2-alkenals, of lipid peroxide-derived oxenes 9-oxo-10(E),12(Z)-octadecadienoic acid (9-KODE) and 13-oxo-9(Z),11(E)-octadecadienoic acid (13-KODE), as well as 4-oxo-(2E)-nonenal and 4-hydroxynonenal. Can use 12-oxo-10(E) dodecanoate (traumatin), trans-1,3 diphenyl-2-propenone, trans-1,4-diphenyl-2-butene-1,4-dione, 9-oxo-12,13-epoxy-(10E)-octadecenoic acid (trans-EKODE-1b) and 9,13-dihydroxy-10-oxo-11-octadecenoic acid as substrates. Catalyzes the reduction of the 7-8 double bond of phenylpropanal substrates, such as p-coumaryl aldehyde and coniferyl aldehyde (in vitro). Has activity towards toxic substrates, such as 4-hydroxy-(2E)-nonenal (in vitro). May play a distinct role in plant antioxidant defense and is possibly involved in NAD(P)/NAD(P)H homeostasis.
|
|||||
TMPY-02271 | TRXR1/TXNRD1 Protein, Human, Recombinant (aa 161-647, His) | Human | E. coli | ||
Thioredoxin reductase 1 (TXNRD1) which is a selenocysteine-containing protein is overexpressed in many malignancies. TXNRD1 plays a key role in regulating cell growth and transformation, and protects cells against oxidative damage. We investigated the association between TXNRD1 polymorphisms and ATDH susceptibility. Moreover, TXNRD1 is an essential selenium-containing enzyme involved in detoxification of reactive oxygen species (ROS) and redox signaling. And genetic variations in TXNRD1 favor the development of Drug-induced liver injury (DILI), which is the most common adverse drug reaction.
|
|||||
TMPH-00098 | AtAER Protein, Arabidopsis thaliana, Recombinant | Arabidopsis thaliana | E. coli | ||
Involved in the detoxification of reactive carbonyls. Acts on lipid peroxide-derived reactive aldehydes. Specific to a double bond activated by an adjacent carbonyl group. Can use both quinones and diamide as substrates, but not menadione, ferricyanide or phylloquinone. Can use 4-hydroxy-(2E)-nonenal (HNE), 4-hydroxy-(2E)-hexenal (HHE), (2E)-nonenal, (2E)-hexenal, (2E)-pentenal, propenal (acrolein), 3-buten-2-one and 3-penten-2-one, but not (R)-(-)-carvone, n-nonanal, n-hexanal, (3Z)-hexanal, cyclohex-2-en-1-one or 12-oxo phytodienoic acid (OPDA) as electron acceptors. Catalyzes the reduction of the alpha,beta-unsaturated bond of 2-alkenals, of lipid peroxide-derived oxenes 9-oxo-10(E),12(Z)-octadecadienoic acid (9-KODE) and 13-oxo-9(Z),11(E)-octadecadienoic acid (13-KODE), as well as 4-oxo-(2E)-nonenal and 4-hydroxynonenal. Can use 12-oxo-10(E) dodecanoate (traumatin), trans-1,3 diphenyl-2-propenone, trans-1,4-diphenyl-2-butene-1,4-dione, 9-oxo-12,13-epoxy-(10E)-octadecenoic acid (trans-EKODE-1b) and 9,13-dihydroxy-10-oxo-11-octadecenoic acid as substrates. Catalyzes the reduction of the 7-8 double bond of phenylpropanal substrates, such as p-coumaryl aldehyde and coniferyl aldehyde (in vitro). Has activity towards toxic substrates, such as 4-hydroxy-(2E)-nonenal (in vitro). May play a distinct role in plant antioxidant defense and is possibly involved in NAD(P)/NAD(P)H homeostasis.
|
|||||
TMPY-02652 | CYB5R1 Protein, Human, Recombinant (His) | Human | E. coli | ||
CYB5R1 Protein, Human, Recombinant (His) is expressed in E. coli with His tag. The predicted molecular weight is 33.5 kDa. Accession number: Q9UHQ9
|
|||||
TMPJ-00955 | MDH1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Malate Dehydrogenase, Cytoplasmic (MDH1) is an enzyme which belongs to the MDH Type 2 sub-family of LDH/MDH superfamily. MDH1 is involved in the Citric Acid Cycle that catalyzes the conversion of Malate into Oxaloacetate (using NAD+) and vice versa. MDH1 should not be confused with Malic Enzyme, which catalyzes the conversion of Malate to Pyruvate, producing NADPH. MDH1 also participates in Gluconeogenesis, the synthesis of Glucose from smaller molecules. Pyruvate in the mitochondria is acted upon by Pyruvate Carboxylase to form Pxaloacetate, a Citric Acid Cycle intermediate. In order to transport the Oxaloacetate out of the Mitochondria, Malate Dehydrogenase reduces it to Malate, and it then traverses the inner Mitochondrial membrane. Once in the cytosol, the Malate is oxidized back to Oxaloacetate by MDH1. Finally, Phosphoenol-Pyruvate Carboxy Kinase (PEPCK) converts Oxaloacetate to Phosphoenol Pyruvate.
|
|||||
TMPY-01812 | Enoyl-ACP Reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Enoyl-ACP reductase, also known as NADH-dependent enoyl-ACP reductase and FABI, is a cell inner membrane and peripheral membrane protein which belongs to theshort-chain dehydrogenases/reductases (SDR) family and FabI subfamily. Microorganisms produce many kinds of antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FABI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. The antibiotic diazaborine interferes with the activity by binding to the protein. FABI is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds.
|
|||||
TMPH-00658 | NAD(P)H-flavin reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Catalyzes the reduction of soluble flavins by reduced pyridine nucleotides.
|
|||||
TMPY-03460 | DCXR Protein, Human, Recombinant (His) | Human | E. coli | ||
DCXR, also known as HCR2, belongs to the short-chain dehydrogenases/reductases (SDR) family. It is highly expressed in kidney, liver and epididymis. In the epididymis, DCXR is mainly expressed in the proximal and distal sections of the corpus region. HCR2 is weakly or not expressed in brain, lung, heart, spleen and testis. DCXR catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose. DCXR participates in the uronate cycle of glucose metabolism. It may play a role in the water absorption and cellular osmoregulation in the proximal renal tubules by producing xylitol, an osmolyte, thereby preventing osmolytic stress from occurring in the renal tubules.
|
|||||
TMPH-01039 | CBR1 Protein, Human, Recombinant (E. coli, His) | Human | E. coli | ||
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
|
|||||
TMPH-01040 | CBR1 Protein, Human, Recombinant (His) | Human | Yeast | ||
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
|
|||||
TMPJ-00207 | AKR1C2 Protein, Human, Recombinant | Human | E. coli | ||
Aldo-Keto Reductase Family 1 Member C2 (AKR1C2) plays a role in concert with the 5-α/5-β-Steroid Reductases to convert Steroid hormones into the 3-α/5-α and 3-α/5-β-Tetrahydrosteroids. AKR1C2 catalyzes the inactivation of the most potent androgen 5-α-Dihydrotestosterone (5-α-DHT) to 5-α-Androstane-3-α, 17-β-diol (3-α-diol).
|
|||||
TMPJ-00460 | MECR Protein, Human, Recombinant (His) | Human | Human Cells | ||
Trans-2-Enoyl-CoA Reductase Mitochondrial (MECR) belongs to the zinc-containing alcohol dehydrogenase family. MECR localizes to the mitochondrion. It is highly expressed in skeletal and heart muscle and expressed at lower levels in the placenta, liver, kidney and pancreas, with weakly or no expression in the lung. MECR exists as a homodimer, which catalyzes the reduction of trans-2-enoyl-CoA to acyl-CoA with chain length from C6 to C16 in an NADPH-dependent manner with preference to medium chain length substrate. MECR may take part in the mitochondrial synthesis of fatty acids.
|
|||||
TMPJ-01111 | TSTA3 Protein, Human, Recombinant (His) | Human | E. coli | ||
GDP-L-Fucose Synthase is a NADP(H)-binding protein. It catalyzes the two-step epimerase and the reductase reactions in GDP-D-mannose metabolism, converting GDP-4-keto-6-D-dexoymannose to GDP-L-fucose. GDP-L-Fucose is the substrate of several fucosyltransferase, involving the expression of mamy glycoconjugates, including blood group ABH antigens and development adhesion antigens. Mutations in the TSTA3 gene may cause leukocyte adhesion deficiency type II.
|
|||||
TMPJ-01098 | PRDX4 Protein, Human, Recombinant (His) | Human | E. coli | ||
Peroxiredoxin-4 (PRDX4) is a member of the AhpC/TSA family. PRDX4 is a cytoplasmic protein and contains one thioredoxin domain. PRDX4 exists in homodimer or heterodimer with PRDX1. PRDX4 reduces hydrogen peroxide and alkyl hydroperoxides to water and alcohol with the use of reducing equivalents derived from thiol-containing donor molecules. In addition, PRDX4 is probably involved in redox regulation of the cell, regulating the activation of NF-kappa-B in the cytosol by a modulation of I-kappa-B-alpha phosphorylation.
|
|||||
TMPH-00683 | TMAO reductase 1 Protein, E. coli O157:H7, Recombinant (His & Myc) | E. coli | E. coli | ||
Reduces trimethylamine-N-oxide (TMAO) into trimethylamine; an anaerobic reaction coupled to energy-yielding reactions.
|
|||||
TMPY-00481 | AKR1C4 Protein, Human, Recombinant (His) | Human | E. coli | ||
Aldo-keto reductases comprise of AKR1C1-AKR1C4, four enzymes that catalyze NADPH dependent reductions and have been implicated in biosynthesis, intermediary metabolism, and detoxification. there is a strong correlation between the expression levels of these family members and the malignant transformation as well as the resistance to cancer therapy. Type I human hepatic 3alpha-hydroxysteroid dehydrogenase (AKR1C4) plays a significant role in bile acid biosynthesis, steroid hormone metabolism, and xenobiotic metabolism.
|
|||||
TMPJ-00463 | BDH2 Protein, Human, Recombinant (His) | Human | E. coli | ||
3-Hydroxybutyrate Dehydrogenase Type 2 belongs to the short-chain dehydrogenases/reductases (SDR) family. 3-Hydroxybutyrate Dehydrogenase Type 2 may play an important role in the peripheral utilization of 3-hydroxybutyrate. The cytoplasmic localization with its high ratio of oxidized NAD+, the NAD+ dependence and the kinetic parameters of 3-Hydroxybutyrate Dehydrogenase Type 2 make it suitable to conbert high levels of circulating 3-hydroxybutyrate into acetoacetate.
|
|||||
TMPH-00160 | Cytochrome P450 BM-3 Protein, Bacillus megaterium, Recombinant (His & Myc) | Bacillus megaterium | E. coli | ||
Cytochrome P450 BM-3 Protein, Bacillus megaterium, Recombinant (His & Myc) is expressed in E. coli.
|
|||||
TMPY-03859 | DHRS9 Protein, Human, Recombinant (His) | Human | E. coli | ||
Dehydrogenase/reductase (SDR family) member 9 (DHRS9) is aberrantly expressed in colorectal cancer (CRC), the decreased expression of DHRS9 correlates with tumor progression and may serve as a potential prognostic biomarker in CRC. The human regulatory macrophage (Mreg) has emerged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant recipients. DHRS9 is a specific and stable marker of human Mregs.
|
|||||
TMPY-03497 | AKR1C2 Protein, Human, Recombinant (His) | Human | E. coli | ||
AKR1C2 is a member of the aldo/keto reductase superfamily, which consists of more than 4 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme binds bile acid with high affinity, and shows minimal 3-alpha-hydroxysteroid dehydrogenase activity. AKR1C2 gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 1p15-p14. Three transcript variants encoding two different isoforms have been found for AKR1C2 gene.
|
|||||
TMPJ-00962 | AKR1C3 Protein, Human, Recombinant (His) | Human | Human Cells | ||
AKR1C3, is an enzyme which belongs to the aldo/keto reductase family. It is expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. AKR1C3 catalyzes the conversion of aldehydes and ketones to alcohols. It catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2,which functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. It can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites.
|
|||||
TMPJ-00934 | PRDX3 Protein, Human, Recombinant | Human | E. coli | ||
Thioredoxin-Dependent Peroxide Reductase Mitochondrial (PRDX3) is an enzyme that belongs to the AhpC/TSA family. Human and mouse PRDX3 genes are highly conserved, and they map to the regions syntenic between mouse and human chromosomes. Human PRDX3 protein has an antioxidant function and is localized in the mitochondrion. PRDX3 is involved in redox regulation of the cell. PRDX3 protects radical-sensitive enzymes from oxidative damage by a radical-generating system. It acts synergistically with MAP3K13 to regulate the activation of NF-kappa-B in the cytosol.
|
|||||
TMPJ-00933 | PRDX5 Protein, Human, Recombinant (His) | Human | Human Cells | ||
Peroxisomes are essential organelles that participate in multiple important metabolic processes, including the β-oxidation of fatty acids, plasmalogen synthesis, and the metabolism of reactive oxygen species (ROS). Peroxiredoxins is overexpressed in breast cancer tissues to a great extent suggesting that they has a proliferative effect and may be related to cancer development or progression. Peroxiredoxin 5 (PRDX5) is a thioredoxin peroxidase that belongs to the atypical 2-Cys class of the TSA/ahpC family of peroxiredoxins. PRDX5 is a widely expressed mitochondrial antioxidant enzyme that reduces hydrogen peroxide, alkyl hydroperoxides, and peroxynitrite. In human cells, this enzyme is present in the cytosol, mitochondria, peroxisomes, and nucleus.
|
|||||
TMPJ-00801 | UQCRH Protein, Human, Recombinant (GST) | Human | E. coli | ||
Cytochrome b-c1 complex subunit 6, mitochondrial (UQCRH) belongs to the UQCRH/QCR6 family, it is a subunit of the respiratory chain protein Ubiquinol Cytochrome c Reductase. This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. UQCRH may mediate formation of the complex between cytochromes c and c1. It may mediate formation of the complex between cytochromes c and c1.
|
|||||
TMPY-03407 | NQO1 Protein, Human, Recombinant (His) | Human | E. coli | ||
NQO1 gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. NQO1 forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one-electron reduction of quinones that results in the production of radical species. Mutations in the NQO1 gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized. Recent pharmacological research suggests the feasibility of genotype-directed redox chemotherapeutic intervention targeting NQO1 breast cancer, a common missense genotype encoding a functionally impaired NQO1 protein.
|
|||||
TMPY-00989 | LDLR Protein, Human, Recombinant (His) | Human | HEK293 | ||
LDL Receptor, also known as LDLR, is a mosaic protein that belongs to the Low-density lipoprotein receptor gene family. The low-density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. LDL Receptor consists of 840 amino acids (after removal of signal peptide) and mediates the endocytosis of cholesterol-rich LDL. Low-density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. LDL Receptor is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants.
|